Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Quteineh L, Vandenberghe F, Gholam Rezaee M, Choong E, Saigi-Morgui N, Delacretaz A, Preisig M, von Gunten A, Conus P, Eap C. CRTC3 polymorphisms are not associated with obesity in Swiss psychiatric populations. Poster presented at the 22nd European Congress of Psychiatry; March 2014. Munich, Germany. [abstract] The european journal of psychiatry. 2014; 29:1.
Vandenberghe F, Gholam Rezaee M, Choong E, Saigi Morgui N, Delacretaz A, Preisig M, von Gunten A, Conus P, Eap C. Predictive values of appetite and early weight increase for long-term weight variation during psychotropic treatment. Poster presented at the 22nd European Congress of Psychiatry; March 2014. Munich, Germany. [abstract] The european journal of psychiatry. 2014; 29(Suppl 1):1. doi: 10.1016/S0924-9338(14)78597-9
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.